FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2286156731> ?p ?o ?g. }

• W2286156731 endingPage "79" @default.
• W2286156731 startingPage "69" @default.
• W2286156731 abstract "Triple negative breast cancer is a subgroup of so-called basal-like breast cancer. They are represented with 15% of all breast cancers, characterized with lack of hormone receptor as well as with negative expression of HER2 test. These tumors are more frequent in Afro-Americans and Latin-Americans, in patients with BRCA1 mutations and in patients with recent delivery. The aim of this study is to present the immunohistochemical and clinico-pathological characteristics of the triple negative breast cancer and their correlation with expression of the protein product of the tumor suppressor gene p53.A retrospective analyses of 24 patients with triple negative breast cancer was performed. All of the patients were evaluated in the Histopathological Laboratory of the Clinical Hospital Sistina, during the period from June 2009, until June 2011. The standard immunohistochemical procedures, including the hormone receptor status, HER2 status, proliferative index - Ki67 and p53 gene protein product were performed, as well as additional immunohistochemical staining for so-called basal keratins (Cytokeratin 5/6 and high molecular weight cytokeratin 34BE12).The age of the patients ranged from 29-77 years. Positive lymph nodes were found in 14 (59%) patients. The tumor was poorly differentiated in 19 patients (79%). Overexpression of the p53 protein product was evaluated in 19 (79%) of the cases. All p53 negative patients (5/5) had poorly differentiated tumors (G3), associated with positive regional lymph nodes. The p53 positive group expressed quite opposite correlation, only 9/19 (47%) were with positive lymph nodes (p = 0.03). The expression of p53 protein product was also associated with the nuclear grade (p = 0.005), the mitotic index (p = 0.001), lymph-vascular invasion (p = 0.005) and with the proliferation index Ki67 (p = 0.003). There was a trend for association with the tumor size - pT (p = 0.05).According to the results, the triple negative breast cancers are subgroup of the poorly differentiated neoplasms frequently associated in the younger age groups. The majority of these have overexpression of the p53 protein product, which in other hand, are inversely correlated with lymph nodes metastases. Hence, the necessity of enriching the immunohistochemical protocol of these patients with new antibodies, in order to evaluate their expression, which would be helpful for prediction the outcome of different therapeutical modalities." @default.
• W2286156731 created "2016-06-24" @default.
• W2286156731 creator A5009853299 @default.
• W2286156731 creator A5011844042 @default.
• W2286156731 creator A5041430778 @default.
• W2286156731 creator A5042805394 @default.
• W2286156731 creator A5051288096 @default.
• W2286156731 date "2015-05-01" @default.
• W2286156731 modified "2023-10-01" @default.
• W2286156731 title "Expression of p53 Protein Product in Triple Negative Breast Cancers and Relation with Clinical and Histopathological Parameters/ Експресија На Р53 Протеинскиот Продукт Кај Тројно Негативните Карциноми На Дојка Во Сооднос Со Клиничките И Хистопатолошките Параметри" @default.
• W2286156731 cites W1554079808 @default.
• W2286156731 cites W1558526836 @default.
• W2286156731 cites W1599113155 @default.
• W2286156731 cites W1965427258 @default.
• W2286156731 cites W1970156673 @default.
• W2286156731 cites W1984045427 @default.
• W2286156731 cites W1988470644 @default.
• W2286156731 cites W1989663680 @default.
• W2286156731 cites W2001968322 @default.
• W2286156731 cites W2010871781 @default.
• W2286156731 cites W202300470 @default.
• W2286156731 cites W2025616449 @default.
• W2286156731 cites W2027139228 @default.
• W2286156731 cites W2038442864 @default.
• W2286156731 cites W2038723222 @default.
• W2286156731 cites W2044929078 @default.
• W2286156731 cites W2054270840 @default.
• W2286156731 cites W2059667789 @default.
• W2286156731 cites W2073098068 @default.
• W2286156731 cites W2077523260 @default.
• W2286156731 cites W2077775719 @default.
• W2286156731 cites W2094764559 @default.
• W2286156731 cites W2097255042 @default.
• W2286156731 cites W2101673433 @default.
• W2286156731 cites W2102596641 @default.
• W2286156731 cites W2106888057 @default.
• W2286156731 cites W2109221809 @default.
• W2286156731 cites W2115603976 @default.
• W2286156731 cites W2120512382 @default.
• W2286156731 cites W2122889158 @default.
• W2286156731 cites W2123963334 @default.
• W2286156731 cites W2128920415 @default.
• W2286156731 cites W2130252153 @default.
• W2286156731 cites W2131994307 @default.
• W2286156731 cites W2135736714 @default.
• W2286156731 cites W2151134970 @default.
• W2286156731 cites W2154730897 @default.
• W2286156731 cites W2155533563 @default.
• W2286156731 cites W2161426850 @default.
• W2286156731 cites W2165662097 @default.
• W2286156731 cites W2166702788 @default.
• W2286156731 cites W2167024869 @default.
• W2286156731 cites W2171015116 @default.
• W2286156731 cites W2317991362 @default.
• W2286156731 cites W2401810515 @default.
• W2286156731 cites W267005183 @default.
• W2286156731 cites W2748036456 @default.
• W2286156731 cites W56145836 @default.
• W2286156731 doi "https://doi.org/10.1515/prilozi-2015-0031" @default.
• W2286156731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26076776" @default.
• W2286156731 hasPublicationYear "2015" @default.
• W2286156731 type Work @default.
• W2286156731 sameAs 2286156731 @default.
• W2286156731 citedByCount "8" @default.
• W2286156731 countsByYear W22861567312015 @default.
• W2286156731 countsByYear W22861567312016 @default.
• W2286156731 countsByYear W22861567312018 @default.
• W2286156731 countsByYear W22861567312019 @default.
• W2286156731 countsByYear W22861567312022 @default.
• W2286156731 countsByYear W22861567312023 @default.
• W2286156731 crossrefType "journal-article" @default.
• W2286156731 hasAuthorship W2286156731A5009853299 @default.
• W2286156731 hasAuthorship W2286156731A5011844042 @default.
• W2286156731 hasAuthorship W2286156731A5041430778 @default.
• W2286156731 hasAuthorship W2286156731A5042805394 @default.
• W2286156731 hasAuthorship W2286156731A5051288096 @default.
• W2286156731 hasBestOaLocation W22861567311 @default.
• W2286156731 hasConcept C121608353 @default.
• W2286156731 hasConcept C126322002 @default.
• W2286156731 hasConcept C142724271 @default.
• W2286156731 hasConcept C143998085 @default.
• W2286156731 hasConcept C204232928 @default.
• W2286156731 hasConcept C207886595 @default.
• W2286156731 hasConcept C2779012181 @default.
• W2286156731 hasConcept C2780110267 @default.
• W2286156731 hasConcept C2780849966 @default.
• W2286156731 hasConcept C530470458 @default.
• W2286156731 hasConcept C71924100 @default.
• W2286156731 hasConcept C84606932 @default.
• W2286156731 hasConcept C98717036 @default.
• W2286156731 hasConceptScore W2286156731C121608353 @default.
• W2286156731 hasConceptScore W2286156731C126322002 @default.
• W2286156731 hasConceptScore W2286156731C142724271 @default.
• W2286156731 hasConceptScore W2286156731C143998085 @default.
• W2286156731 hasConceptScore W2286156731C204232928 @default.
• W2286156731 hasConceptScore W2286156731C207886595 @default.
• W2286156731 hasConceptScore W2286156731C2779012181 @default.
• W2286156731 hasConceptScore W2286156731C2780110267 @default.

• next